2788 J ournal of Medicinal Chemistry, 2003, Vol. 46, No. 13
Villhauer et al.
Demuth, H.-U.; Brownsey, R.; Parkhouse, W.; Finegood, D. T.;
McIntosh, C. H. S. Pederson, R. A. Long-Term Treatment with
the Didpeptidyl Peptidase IV Inhibitor P32/98 causes sustained
improvements in glucose tolerance, insulin sensitivity, hyper-
insulinemia, and â-cell glucose responsiveness in VDF (fa/fa)
Zucker Rats. Diabetes 2002, 51, 943-950.
ferentiation of Human Pancreatic Islet-Derived Progenitor Cells
into Insulin-Producing Cells. Endocrinology 2002, 143 (8), 3152-
3161. (h) Tourrel, C.; Bailbe, D.; Lacorne, M.; Meile, M. J .;
Kergoat, M.; Portha, B. Persistent Improvement of Type 2
Diabetes in the Goto-Kakizaki Rat Model by Expansion of the
B-Cell Mass During the Prediabetic Period with Glucagon-Like
Peptide-1 or Exendin-4. Diabetes 2002, 51, 1443-1452. (i)
Perfetti, R.; Zhou, J .; Doyle, M. E.; Egan, J . M. Glucagon-Like
Peptide -1 Induces Cell Proliferation and Pancreatic-Duodenum
Homeobox-1 Expressoin and Increases Endocrine Cell Mass in
the Pancreas of Old, Glucose-Intolerant Rats. Endocrinology
2000, 141 (12), 4600-4605. (j) Li, Y.; Hansotia, T.; Yusta, B.;
Ris, F.; Halban, P. A.; Drucker, D. J . Glucagon-like Peptide-1
Receptor Signaling Modulates beta Cell Apoptosis. J . Biol. Chem.
2003, 278 (1), 471-478.
(9) (a) Balkan, B.; Kwasnik, L.; Miserendino, R.; Holst, J . J .; Li, X.
Inhibition of dipeptidyl peptidase IV with NVP-DPP728 in-
creases plasma GLP-1 (7-36 amide) concentrations and im-
proves oral glucose tolerance in obese Zucker rats. Diabetologia
1999, 42 (11), 1324-1331. (b) Mitani, H.; Takimoto, M.; Hughes
T. E.; Kimur, M. Dipeptidyl peptidase IV inhibition improves
impaired glucose tolerance in high-fat diet-fed rats: study using
a Fisher 344 rat substrain deficient in its enzyme activity.
J apanese J ournal of Pharmacology 2002, 88, 442-450. (c)
Mitani, H.; Takimoto, M and Kimura, M. Dipeptidyl peptidase
IV inhibitor, NVP-DPP728, ameliorates early insulin response
and glucose tolerance in aged rats but not in aged Fisher 344
rats lacking its enzyme activity. J pn J . Pharmacol. 2002, 88,
451-458.
(10) Sudre, B.; Broqua, P.; White, R. B.; Ashworth, D.; Evans, E. M.;
Haigh, R.; J unien, J .-L.; Aubert, M. L. Chronic Inhibition of
Circulating Dipeptidyl Peptidase-IV by FE 999011 Delays the
Occurrence of Diabets in Male Zucker Diabetic Fatty Rats.
Diabetes 2002, 51, 1461-1469.
(11) Marguet, D.; Baggio, L.; Kobayashi, T.; Bernard, A.-M.; Pierres,
M.; Nielsen, P. F.; Ribel, U.; Wantanabe, T.; Drucker, D. J .;
Wagtmann, N. Enhanced insulin secretion and improved glucose
tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. U.S.A.
2000, 97, 6864-6879.
(12) Holst, J . J .; Deacon, C. F. Inhibition of the activity of Dipeptidyl-
Peptidase IV as a treatment for Type 2 Diabetes. Diabetes 1998,
47, 1663-1670. (b) Zander, M.; Madsbad, S.; Madsen, J . L.;
Holst, J . J . Effect of 6-week course of glucagon-like peptide 1 on
glycaemic control, insulin sensitivity, and â-cell function in type
2 diabetes; a parallel-group study. Lancet 2002, 359, 824-830.
(13) (a) Ahren, B.; Larsson, J .; Holst, J . J . Effects of glucagon-like
peptide-1 on islet function and insulin sensitivity in noninsulin
dependent diabetes mellitus. J . Clin. Endocrinol. Metab. 1997,
82, 473-478. (b) Rachman, J .; Borrow, B. A.; Levy, J . C.; Turner
R. C. Near normalizatoin of diurnal glucose concentrations by
continuous administration of glucagon-like peptide 1 (GLP-1)
in subjects with NIDDM. Diabetologia 1997, 40, 205-211. (c)
Nauck, M. A.; Wollschlager, D.; Werner, J .; Holst, J . J .; Orskov,
C.; Creutzfeldt, W.; Willms, B. Effects of subcutaneous glucagon-
like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
Diabetologia 1996, 39, 1546-1553. (d) Drucker, D. J . Biological
actions and therapeutic potential of the glucagon-like peptides.
Gastroenterology 2002, 122 (2), 531-544. (e) Egan, J .; Clocquet,
A. R.; Elahi, D. The Insulinotropic Effect of Acute Exendin-4-
administered to Humans: Comparison of Nondiabetic State to
Type 2 Diabetes. J . Clin. Endocrinol. Metab. 2002, 87 (3), 1282-
1290.
(16) (a) Flint, A.; Raben, A.; Ersboll, A. K.; Holst, J . J .; Astrup, A.
The effect of physiological levels of glucagon-like peptide-1 on
appetite, gastric emptying, energy and substrate metabolism in
obesity. Int. J . Obes. 2001, 25, 781-792.
(17) (a) Doyle, M. E.; Egan, J . M. Glucagon-like peptide-1. Recent
Prog. Horm. Res. 2001, 56, 377-399. (b) Villanueva-Pen˜acarrillo,
M. L.; Puente, J .; Redondo, A.; Clemente, F.; Valverde, I. Effect
of GLP-1 treatment on GLUT2 and GLUT4 expression in Type
1 and Type 2 rat diabetic models. Endocrine 2001, 15 (2), 241-
248. (c) Sandhu, H.; Wiesenthal, S. R.; MacDonald, P. E.; McCall,
R. H.; Tchipashvili, V.; Rashid, S.; Satkunarajah, M.; Irwin, D.
M.; Shi, Z. Q.; Brubaker, P. L.; Wheeler, M. B.; Vranic, M.;
Efendic, S.; and Giacca, A. Glucagon-Like Peptide 1 increases
inslin sensitivity in depancreatized dogs. Diabetes 1999, 48,
1045-1053. (d) Pospisilik, J . A.; Stafford, S. G.; Demuth, H.-U.;
McIntosh, H. S.; Pederson, R. A. Long-Term Treatment with
Dipeptidyl Peptidase IV Inhibitor Improves Hepatic and Pe-
ripheral Insulin Sensitivity in the VDF Zucker Rat - A Eugly-
cemic-Hyperinsulinemic Clamp Study. Diabetes 2002, 51, 2677-
2683.
(18) (a) Burcelin, R.; Da Costa, A.; Drucker, D.; Thorens, B. Glucose
competence of the hepatoprotal vein sensor requires the presence
of an activated glucagon-like peptide-1 receptor. Diabetes 2001,
50, 1720-1728. (b) Balkan, B.; Li, X. Portal GLP-1 administra-
tion in rats augments the insulin response to glucose via
neuronal mechanisms. Am. J . Physiol. Regul. Integ. Comput.
Physiol. 2000, 279: R1449-R1454.
(19) (a) J uana, F.; Valdeolmillos, M. Glucose-dependent stimulatory
effect of glucagon-like peptide 1(7-36) amide on the electrical
activity of pancreatic â-cells recorded in vivo. Diabetes 1999, 48
(4), 754-757. (b) Nauck, M. A.; Heimessat, M. M.; Behle, K.;
Holst, J . J .; Nauck, M. S.; Ritzel, R.; Hufner, M.; Schmiegel,
Wolff, H. Effects of glucagon-like peptide 1 on counterregulatory
hormone responses, cognitive functions, and insulin secretion
during hyperinsulinemic, stepped hypoglycemic clamp experi-
ments in healthy volunteers. J . Clin. Endocrinol. Metab. 2002,
87 (3), 1239-1246.
(20) These nonsubstrate DPP-IV inhibitors provide low micromolar
IC50’s, and, except for refs 20(a) and 20(b), contain a protona-
table amine: (a) Shimazawa, R.; Takayama, H.; Kato, F.; Kato,
M.; Hashimoto, Y. Nonpeptide small-molecular inhibitors of
Dipeptidyl Peptidase IV; N-phenylphthalimide analogues. Bioorg.
Med. Chem. Lett. 1999, 9, 559-562. (b) Miyachi, H.; Kato, M.;
Kato, F.; Hashimoto, Y. Novel potent nonpeptide aminopeptidase
N inhibitors with a cyclic imide skeleton. J . Med. Chem. 1998,
41, 3, 263-265. (c) Yamada, M.; Okagaki, C.; Higashijima, T.;
Tanaka, S.; Ohnuki, T.; Sugita, T. A potent dipeptide inhibitor
of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett. 1998, 8,
1537-1540. (d) Coppola, G. M.; Zhang, Y. L.; Schuster, H. F.;
Russell, M. E.; Hughes T. E. 1-Aminomethylisoquinoline-4-
carboxylates as novel Dipeptidyl Peptidase IV inhibitors. Bioorg.
Med. Chem. Lett. 2000, 10, 1555-1558. (e) Kanstrup, A. B.;
Christiansen, L. B.; Lundbeck, J . M.; Kristiansen; M. Prepara-
tion of piperazinylpurinediones as inhibitors of dipeptidylpep-
tidase IV. Patent WO 02002560, J uly 4th, 2002.
(21) Irreversible oligopeptides with the N-terminal X-Pro-X sequence
(low micromolar IC50) - Rahfeld, J .; Schierhorn, M.; Hartrodt,
B.; Neubert, K.; Heins, J . Are Diprotin A and (Ile-Pro-Ile) and
Diprotin B (Val-Pro-Leu) Inhibitors or Substrates of Dipeptidyl
Peptidase IV? Biochim. Biophys. Acta 1991, 1076, 314-316.
(22) Suicide substrate (latent quinoniminium methide electrophile
- large cyclopeptide). Nguyen, C.; Blanco, J .; Mazaleyrat, J . P.;
Krust, B.; Callebaut, C.; J acotot, E.; Hovanessian, A. G.;
Wakselman, M. Specific and Irreversible Cyclopeptide Inhibitors
of Dipeptidyl Peptidase IV Activity of the T-Cell Activation
Antigen CD26. J . Med. Chem. 1998, 41, 2100-2110.
(14) (a) Wettergren, A.; Schjoldager, B.; Martensen, P. E.; Myhre,
J .; Christiansen, J .; Holst, J . J . Truncated GLP-1 (proglucagon
72-107 amide) inhibits gastric and pancreatic functions in
man. Dig. Dis. Sci. 1993, 38, 665-673. (b) Nauck, M. A.;
Niedereichholz, U.; Ettler, R.; Holst, J . J .; Orskov, C.; Ritzel,
R.; Schmigel, W. H. Glucagon-like peptide-1 inhibition of gastric-
emptying outweighs its insulinotropic effects in healthy humans.
Am. J . Physiol. 1997, 273, E981-E988. (c) Nauck, M. A. Is GLP-1
an incretin hormone? Diabetologia 1999, 42, 373-379. (d) Egan,
J .; Clocquet, A. R.; Elahi, D. The Insulinotropic Effect of Acute
Exendin-4-Administered to Humans: Comparison of Nondia-
betic State to Type 2 Diabetes. J . Clin. Endocrinol. Metab. 2002,
87 (3), 1282-1290.
(15) (a) Habener, J . F. Glucagonlike peptide-1 agonist stimulation
of â-cell growth and differentiation. Curr. Opin. Endocrinol.
Diabetes 2001, 8 (2), 74-81. (b) Ling, Z.; Wu, D.; Zambre, Y.;
Flamez, D.; Drucker, D. J .; Pipeleers, D. G.; Schuit, F. C.
Glucagon-like peptide 1 receptor signaling influences topography
of islet cells in mice. Virchows Arch. 2001, 438 (4), 382-387. (c)
Aspelun, F.; Egan, J . M.; Slezak, L. A.; Sritharan, K. C.; Elahi,
D.; Andersen, D. K. Glucagon-like peptide-1 and exendin-4
improve glucose tolerance and induce islet cell growth in
pancreatitis in rats. Surg. Forum 2000, 51, 40-42. (d) Kemp,
D. M.; Habener, J . F. Insulinotropic hormone glucagon-like
peptide 1 (GLP-1) activation of insulin gene promoter inhibited
by p38 mitogen-activated protein kinase. Endocrinology 2001,
142 (3), 1179-1187. (e) Parkes, D. G.; Pittner, R.; J odka, C.;
Smith, P.; Young, A. Insulinotropic actions of exendin-4 and
glucagon-like peptide-1 in vivo and in vitro. Metab. Clin. Exp.
2001, 50 (5), 583-589. (f) Farilla, L.; Hui, H.; Berolotto, C.; Kang,
E.; Bulotta, A.; Di Mario, U.; Perfetti, R.. Glucagon-like Peptide-1
promotes islet cell growth and inhibits apoptosis in Zucker
diabetic rats. Endocrinology 2002, 143 (11), 4397-4408. (g)
Abraham, E. J .; Leech, C. A.; Lin, J . C.; Zuelwski, H.; Habener,
J . F. Insulinotropic Hormone Glucagon-Like Peptide-1 dif-
(23) Heins, J .; Welker, P.; Scho¨nlein, C.; Born, I.; Hartrodt, B.;
Neubert, K.; Tsuru, D.; Barth, A. Mechanism of Proline-Specific
Proteinases; (I) Substrate Specificity of Dipeptidyl Peptidase IV
from Pig Kidney and Protein-Specific Endopeptidase from Fla-
vobacterium meningosepticum. Biochim. Biophys. Acta 1988,
954, 161-169.